; (B) make recommendations to the Secretary regarding any appropriate changes or improvements to such activities and research; and (C) solicit input from States, localities, and nongovernmental entities, including organizations representing patients, health care providers, researchers, and industry regarding scientific advances, research questions, and surveillance activities. (3) Membership The members of the Working Group shall represent a diversity of scientific disciplines and views and shall be composed of the following members: (A) Federal members Seven Federal members, consisting of one or more representatives of each of the following: (i) The Office of the Assistant Secretary for Health. (ii) The Food and Drug Administration. (iii) The Centers for Disease Control and Prevention. (iv) The National Institutes of Health. (v) Such other agencies and offices of the Department of Health and Human Services as the Secretary determines appropriate. (B) Non-Federal public members Seven non-Federal public members, consisting of representatives of the following categories: (i) Physicians and other medical providers with experience in diagnosing and treating Valley Fever. (ii) Scientists or researchers with expertise. (iii) Patients and their family members. (iv) Nonprofit organizations that advocate for patients with respect to Valley Fever. (v) Other individuals whose expertise is determined by the Secretary to be beneficial to the functioning of the Working Group. (4) Meetings The Working Group shall meet annually. (5) Reporting Not later than 2 years after the date of enactment of this Act, and every 2 years thereafter until termination of the Working Group pursuant to paragraph (7), the Working Group shall— (A) submit a report on its activities under paragraph (2)(A) and any recommendations under paragraph (2)(B) to the Secretary, the Committee on Energy and Commerce of the House of Representatives, and the Committee on Health, Education, Labor, and Pensions of the Senate